Late-Breaking Clinical Trials Submission Guidelines

The Heart Rhythm Society recognizes that exciting and rapidly evolving research was not concluded in time for the December 1, 2017 abstract submission deadline. In an effort to highlight timely and novel work at Heart Rhythm 2018, the Scientific Sessions Program Committee developed a peer-reviewed session of late-breaking clinical trials that allows for later submission.

Important Information
The Late Breaking Clinical Trial session submission site will open Friday, February 2, 2018. All submissions must be received no later than Friday, March 9, 2018, 11:59 p.m. EST. The Heart Rhythm Society is not responsible for submissions not submitted by this date. Abstracts Submitted March 10, 2018, midnight EST will not be accepted. Authors will be notified about the acceptance/rejection of their abstract on March 30, 2018, via email.

Abstract Author Designation
The Submitting Author is the Presenting Author and listed as the First Author. The submittal of an abstract by the Submitting Author will automatically populate the submission information for the Presenting Author and First Author fields. All correspondence for the abstract will be directed to the Submitting Author. The information should be reviewed to ensure that current and correct email address information is listed. The designation of Submitting/Presenting/First Author should be carefully considered before initiating the abstract submission process. Once the abstract has been submitted, the Submitting Author/Presenting Author/First Author cannot be changed.

Criteria
Evaluation will be based on the following criteria:
1. Impact of the research
2. Novelty and rigor of the study design
3. Clinical endpoints
4. Quality of the statistical plan

Rules for Submission Eligibility
• If an abstract submission covering the results of this late-breaking trial is accepted for the Heart Rhythm 2018 meeting, the trial will not be eligible for the Late-Breaking Clinical Trials session.
• Submissions are not eligible for consideration if the manuscript of the submission will be published prior to Heart Rhythm 2018.
• Submissions are not eligible for consideration if the trial results have been presented at a major international meeting held prior to Heart Rhythm 2018.
• Submissions that appear to be redundant versions of a single study will be rejected.
• Submissions that are selling a product versus discussing the science will be rejected.

Investigator Requirements
• The first investigator listed in the abstract shall be considered the presenter. Only one investigator per trial may be considered the presenter.
• The submitting investigator must guarantee that all co-authors are familiar with the data, agree with the stated results, and have agreed to be included as authors.
• If an investigator belongs to multiple submissions, the investigator’s name must be identical in each submission. This will ensure consistency and assist in the indexing process for all Heart Rhythm 2018 publications.
• A completed submission constitutes a commitment by an investigator to present if accepted.
ABSTRACT SUBMISSION AND PREPARATION GUIDELINES

Abstract Title
• All abstracts require a short, specific title (unabbreviated) indicating the nature of the investigation.

Abstract Author
The Submitting Author is the Presenting Author and listed as the First Author. The submittal of an abstract by the Submitting Author will automatically populate the submission information for the Presenting Author and First Author fields. All correspondence for the abstract will be directed to the Submitting Author. The information should be reviewed to ensure that current and correct email address information is listed. The designation of Submitting/Presenting/First Author should be carefully considered before initiating the abstract submission process. Once the abstract has been submitted, the Submitting Author/Presenting Author/First Author cannot be changed.
  • Only one investigator per trial may be considered the Presenting Author.
  • The Submitting Author must guarantee that all co-authors are familiar with the data, agree with the stated results, and have agreed to be included as authors.
  • If an investigator belongs to multiple submissions, the investigator’s name must be identical in each submission. This will ensure consistency and assist in the indexing process for all Heart Rhythm 2018 electronic and printed materials.
  • A completed submission constitutes a commitment by an investigator to present if accepted.

Abstract Text
When entering text, please remember:
• Use generic drug names.
• Do not begin sentences with numerals.
• Standard abbreviations may be used without definition. Non-standard abbreviations (kept to a minimum) must be placed in parentheses after the first use of the word or phrase abbreviated.
• Do not include references, credits, or grant support.
• Do not include the names or personal information of any patient participating in the study or trial.

Please note that because of the text box system, you will not be able to upload your abstract to the Abstract Submission Site; you must either type the text in or cut and paste the text from another document. You will still be able to upload images and create tables the same way as before.

Abstract Data
• Multiple abstracts appearing to be redundant versions of a single study will be rejected.
• Abstracts are not eligible for consideration if published prior to the 39th Annual Scientific Sessions. Abstracts may not be presented at the Annual Scientific Sessions if they are substantially similar to material presented at a major international meeting held prior to the Annual Scientific Sessions.
• Individuals who have submitted abstracts to other major international meetings and are awaiting notification of acceptance may also submit abstracts to the Heart Rhythm Society for consideration for the 39th Annual Scientific Sessions; however, upon acceptance from another organization, it is the responsibility of the author to notify the Heart Rhythm Society office by Friday, April 6, 2018, 11:59 p.m. EST to withdraw the abstract.
• The Scientific Sessions Program Committee endorses the position of the American Association for the Advancement of Science in requiring assurances of the responsible use of animals in research (AAAS Resolution: Use of Animals in Research, Testing, and Education). All submissions must be in compliance with these guidelines.
• Any human experimentation must conform to the principles of the Declaration of Helsinki of the World Medical Association (WMA Declaration of Helsinki).
• The Presenting Author must ensure that all co-authors are familiar with the data, agree with the stated results, and have agreed to be included as authors.
• The Heart Rhythm Society reserves the rights of reproduction, distribution, display and derivatives in both print and digital format. Upon their abstract’s acceptance, authors will be asked to read and comply with the Heart Rhythm Society’s Release and Authorization for CD-ROMs, Webcasts, and Enduring Products.
Abstract Format
The total number of characters allowed for the submission is 2500. The character count only includes the abstract title, text, tables and/or images. The character count does not include author(s) information and spaces. As you enter text into the abstract title, a counter deducts characters from the total allowable number of characters.

The Abstract Body text is to be provided as follows:
  Introduction:
  Methods:
  Application:
  Next Steps/Future:

Characters are also deducted when you create a table or upload a graphic. The number of characters deducted for each table or graphic is 500. Please be sure that any text included in the graphic will be legible at the size you define for the graphic.

Figures:
Figures should be submitted in one of the following file formats: EPS, TIFF, or JPEG. For TIFF or JPEG files, the resolution should be
  Line art: 1000 dpi
  Photos: 300 dpi
  Combination line/half-tones: 500 dpi

Abstract Revisions
- Carefully proofread the abstract content and make any necessary revisions before the submission deadline date.
- To ensure that the abstract receives proper scientific consideration, please make sure that the abstract is submitted to the appropriate category. This determines which team grades the abstract. If you select the appropriate category, you are more likely to be graded by peers with similar interests.
- Resubmission of an abstract that is corrected or changed is not possible after the submission deadline date.

Accepted Submissions
  General Information
  - Acceptance/Rejection Notification: Disposition announcements will be sent via email on Friday, March 30, 2018 to the investigator submitting the late breaking trial.
  - Accepted Late-Breaking Clinical Trials abstracts are embargoed until the time of presentation. This means that the Society will release these abstracts the day of the presentation.
  - The Heart Rhythm Society reserves the rights of reproduction, distribution, display and derivatives in both print and digital format. Co-authors reserve all proprietary rights other than copyright, such as patent rights and the right to use all or part of the application in future works of their own.
  - Titles and presenters will be listed online in the Heart Rhythm 2018 Program/Itinerary Planner. A copy of the abstracts will be handed out at the beginning of each Late-Breaking Clinical Trials Session.
  - The Late-Breaking Clinical Trial abstracts will be published on the HeartRhythm website in May 2018 shortly after Heart Rhythm 2018 and included in the June issue of the HeartRhythm journal.
  - Authors of accepted abstracts are encouraged to submit full articles of their findings to HeartRhythm for expedited peer review and potential publication in the journal soon after the presentation. See the HeartRhythm author guidelines for information on manuscript preparation and submission.
  - Disclosure of Relationships: The presenting author will be required to provide the Heart Rhythm Society with the relationships they need to disclose.

Registration
- The presenter of the trial will be required to register for Heart Rhythm 2018 and will be charged a reduced registration rate; please visit the Registration & Housing webpage for more information. Expenses associated with the submission and presentation of an abstract are the responsibility of the presenter. Only one author per abstract is considered the presenter. Co-Author(s) listed on the abstract do not receive reduced rates towards registration. Registration information will be sent to Presenting Authors that have been accepted for presentation in March. For more information, visit the Faculty Resources section of the Heart Rhythm Society’s website at www.HRSonline.org.
• All expenses incurred by the presenter for submission and presentation are the responsibility of the presenter.

**Presentation**

• The submitting investigator will be asked to reconfirm all co-author information, supply presentation information and inform the Heart Rhythm Society staff of any additional audiovisual needs. PowerPoint presentations have become the standard for Heart Rhythm 2018 meeting. Additional information will be provided with acceptance information.

• Presenters should prepare for a 15-minute time slot, with 12 minutes for presentation and three minutes for questions.

• All presenters must display a slide at the beginning of their presentation indicating disclosure information that may be applicable. Detailed information about slides and disclosing relationships will be provided to all presenters.

• All presentations and discussions must be conducted in English.

**Questions**

If you have any questions about submitting an abstract for presentation at Heart Rhythm 2018, please contact Kristian Adams, Manager, Scientific Sessions & Education: abstracts@hrsonline.org.